To uncover the role of microRNA-339-5p (miRNA-339-5p) in the development of gastric cancer (GC) and its possible molecular mechanism. Differential expressions of miRNA-339-5p in GC and adjacent normal tissues were detected. The relationship between miRNA-339-5p level and clinical features in GC patients was analyzed. Proliferative and migratory changes in BGC-823 and SGC-7901 cells overexpressing miRNA-339-5p were examined. Finally, luciferase assay and rescue experiments were conducted to explore the regulatory mechanism of miRNA-339-5p in its downstream gene ALKBH1, and their interaction in the development of GC. MiRNA-339-5p was downregulated in GC tissues. Lowly expressed miRNA-339-5p was unfavorable to prognosis in GC because of high rates of lymphatic metastasis and distant metastasis. Overexpression of miRNA-339-5p markedly reduced proliferative and migratory abilities in GC cells. ALKBH1 was identified to be the downstream gene of miRNA-339-5p. In GC tissues, ALKBH1 was upregulated and negatively correlated to miRNA-339-5p level. Overexpression of ALKBH1 was able to reverse the inhibitory effects of overexpressed miRNA-339-5p on proliferative and migratory abilities in GC. Lowly expressed miRNA-339-5p is closely related to metastasis and poor prognosis in GC patients. MiRNA-339-5p suppresses the malignant development of GC by negatively regulating ALKBH1.
The prognosis of patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma is still dismal. There are no standard treatment strategies for these patients. Multidisciplinary team (MDT) approach is a good choice for making a high-quality decision. Generally, MDT will recommend these patients to receive preoperative chemotherapy or preoperative chemoradiation based on all kinds of treatment guidelines. However, the preferred preoperative treatment is still not established. In order to solve this problem, we carry out this randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma. Eligible patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma are randomized to receive preoperative chemoradiation or preoperative chemotherapy, followed by surgery and postoperative chemotherapy. In the preoperative chemoradiation arm (Pre-CRT), patients receive two cycles of S-1 and oxaliplatin (SOX), chemoradiation, then followed by surgery and three more cycles of SOX chemotherapy. In the preoperative chemotherapy arm (Pre-CT), patients receive three cycles of SOX, following surgery three more cycles of SOX are given. The primary endpoint of this trial is to verify that preoperative chemoradiation could significantly improve the 3-year disease free survival (DFS) of patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma compared to preoperative chemotherapy. The results from this trial will provide important information about whether preoperative chemoradiation could improve survival compared to preoperative chemotherapy among patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma. ClinicalTrials.gov Identifier: NCT03013010. First posted January 6, 2017.
Background/Objectives: The utility of routine gastric tube (GT) placement following gastrectomy in gastric cancer (GC) patients with pyloric obstruction remains controversial. This practice conflicts with Enhanced Recovery After Surgery (ERAS) principles, and its value in this high-risk subgroup is unclear. This study aimed to compare the clinical and economic outcomes of routine versus selective gastric tube use in these patients, and to identify predictors for prolonged gastric tube retention. Methods: A single-center retrospective cohort study was conducted on 133 GC patients with pyloric obstruction who underwent gastrectomy. Patients were stratified into GT (n = 63) and non-GT (n = 70) groups. Primary outcomes included 30-day complications, 90-day mortality, hospitalization duration, and costs. Univariate and multivariable Cox regression analyses were used to identify predictors of prolonged GT retention. Results: Routine GT use provided no clinical benefit, with similar 30-day complication (22.2% vs. 22.9%, p = 0.945) and 90-day mortality (1.6% vs. 0%, p = 0.290) rates. However, it was associated with a significantly prolonged postoperative hospital stay (8.8 ± 2.5 vs. 8.0 ± 4.2 days, p = 0.034) and a mean cost increase of ¥5900 per patient (p = 0.006). A dose–response relationship was evident: each additional day of GT retention correlated with 0.57 extra hospital days (r = 0.567, p < 0.001) and ¥3600 in added costs (r = 0.360, p = 0.004). Multivariable analysis identified longer preoperative fasting time (Adjusted HR = 1.27 per hour, 95% CI: 1.10–1.45, p = 0.001) and GLIM-defined malnutrition (Adjusted HR = 2.04, 95% CI: 1.02–4.17, p = 0.045) as independent predictors for prolonged GT retention. Conclusions: Routine GT placement after gastrectomy in obstructed GC patients increases healthcare costs and prolongs hospitalization without improving clinical outcomes. Preoperative fasting duration and nutritional status are key predictors for prolonged GT need. A selective GT strategy, guided by these parameters, is recommended to optimize recovery and resource utilization, aligning with ERAS principles.